|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
Biomarker
|
disease |
BEFREE |
NAT2 ultra-slow acetylator and risk of anti-tuberculosis drug-induced liver injury: a genotype-based meta-analysis.
|
29781872 |
2018 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, our results suggest that the NAT2 slow acetylator, in particular, the NAT2 slow acetylator combined with smoking, are associated with an increased bladder cancer risk.
|
26585839 |
2016 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further stratification of our study subjects based on different risk factor status showed that the increased risk for an NAT2 slow acetylator was more marked in post-menopausal women who were not using HRT or who had a lower BMI.
|
10389748 |
1999 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
Biomarker
|
disease |
BEFREE |
The gene diagnosis of N-acetyltransferase 2 suggested that the type was classified as NAT2*6A/*7B, indicating that the patient was a slow acetylator.
|
12795783 |
2003 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
Biomarker
|
disease |
BEFREE |
NAT2 slow acetylator smokers had significantly lower stable aberration frequencies compared to the NAT2 rapid acetylator smokers.
|
10862522 |
2000 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
Biomarker
|
disease |
BEFREE |
NAT2 slow acetylator function as a risk indicator for age-related cataract formation.
|
12724621 |
2003 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
Biomarker
|
disease |
BEFREE |
The slow acetylator status of NAT2 is a significant susceptibility risk factor for ATDH.
|
20392357 |
2010 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results indicate that NAT2 slow acetylator genotypes may be an important genetic determinant for DM in the Turkish population.
|
16397907 |
2007 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
Biomarker
|
disease |
BEFREE |
Verified predominance of slow acetylator phenotype N-acetyltransferase 2 (NAT2) in a Hmong population residing in Minnesota.
|
16799928 |
2006 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
Biomarker
|
disease |
BEFREE |
The slow acetylator status of N-acetyl transferase 2 (NAT2) is a well-established risk factor for ATDH.
|
31066138 |
2019 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
Biomarker
|
disease |
BEFREE |
When stratifying for race, the pooled ORs for NAT2 slow acetylator were 1.99 (95% CI = 1.10-3.63) in Asians and 0.85 (95% CI = 0.62-1.15) in Caucasians, and the pooled ORs for NAT2 rapid acetylator were 0.50 (95% CI = 0.28-0.91) in Asians and 1.18 (95% CI = 0.87-1.60) in Caucasians.
|
21877196 |
2011 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Results:</b> NAT2 slow acetylator was significantly associated with AT-DILI risk (p = 2.7 × 10<sup>-7</sup>; odds ratio [95% CI] = 3.64 [2.21-6.00]).
|
31699005 |
2019 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
Biomarker
|
disease |
BEFREE |
NAT2 slow acetylator associated with anti-tuberculosis drug-induced liver injury in Thai patients.
|
27725049 |
2016 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, there was a synergic effect of NAT2 slow acetylator and well-done meat intake to the development of GNA (odds ratio = 3.83; 95% confidence interval, 1.68-8.76, p = 0.001).
|
26617241 |
2016 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, slow acetylator status of NAT2 was a significant susceptibility risk factor for antituberculosis drug-induced hepatotoxicity; NAT2 genotyping may be a useful tool for predicting antituberculosis drug-induced hepatotoxicity.
|
17950035 |
2007 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, slow-acetylator status of NAT2 is a significant susceptibility risk factor for antituberculosis drug-induced hepatitis.
|
11915035 |
2002 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
Biomarker
|
disease |
BEFREE |
Phenotypes reconstructed after haplotype analyses showed that the carriers of the combined NAT1 fast+ NAT2 fast phenotypes were at lower risk when compared with those with the combined NAT1 slow + NAT2 slow acetylator phenotypes.
|
17259654 |
2007 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results therefore suggest that NAT2 slow acetylator genotype may be an important modifier of environmentally induced breast cancer risk in Finnish women.
|
15609332 |
2005 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
For 114 cases with breast cancer and 280 controls with benign breast disease, NAT2 genotype was determined using allele-specific PCR amplification to detect slow acetylator mutations.
|
10753193 |
2000 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The presence of NAT2 slow acetylator genotype, and CYP1A2, GSTA1, and GSTM3 variants were associated with an average 3-5 fold increased risk.
|
25719551 |
2015 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
When comparing the extreme genotype combinations of the NAT2 rapid acetylator, higher mEH activity genotype to the NAT2 slow acetylator, and very low mEH activity genotype, the corresponding ORs at 0 and 80 pack-years were 0.30 (95% CI, 0.14-0.62) and 2.19 (95% CI, 1.26-3.81), respectively.
|
11815396 |
2002 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Compared to women with the slow acetylator genotype, the main effects odds ratios (OR) for NAT2 were 1.4 for the intermediate acetylator genotype (95% confidence limits (CL) 0.7, 2.7) and 3.6 for the homozygous rapid acetylator genotype (95% CL 1.1, 11.4) (P for trend = 0.05).
|
15225898 |
2004 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, the ADRs emerged earlier in the AS cases carrying both NAT1 and NAT2 slow acetylator genotypes.
|
25413361 |
2014 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Hepatic dysfunction in NAT2 slow acetylator recipient patients during the 6-month period after SMX administration was not observed.
|
22106207 |
2012 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
NAT2 slow acetylator genotype is associated with increased risk of lung cancer among non-smoking Chinese women in Singapore.
|
10469638 |
1999 |